Association of ARRB1 polymorphisms with the risk of major depressive disorder and with treatment response to mirtazapine

Hun Soo Chang, Eun Soo Won, Hwa Young Lee, Byung-Joo Ham, Yong Gu Kim, Min-Soo Lee

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

β-Arrestin 1 is known to be involved in the pathophysiology of major depressive disorder (MDD) and in the underlying mechanism of action of antidepressant therapies. After we screened 39 ARRB1 polymorphisms, we investigated the associations of seven ARRB1 single-nucleotide polymorphisms (SNPs) with the risk of MDD in 270 patients with MDD and 204 normal subjects, and with mirtazapine treatment response in patients with MDD. The genotype distributions of -132C>T and IVS1+85T>C showed significant deviations from Hardy-Weinberg equilibrium in patients with MDD but not in normal subjects. After four and 12 weeks of mirtazapine treatment, the proportion of haplotype 1 (ht1) carriers was significantly higher in remitters than in non-remitters after corrections for multiple comparisons (corrected p=0.006 and 0.014 at four and 12 weeks, respectively). After eight and 12 weeks of treatment, scores on the 21-item Hamilton Depression Rating Scale (HAMD21) were significantly lower in patients with MDD with ARRB1 ht1 than in those without ht1. Similarly, after 8 and 12 weeks of treatment, the percent reduction in HAMD21 scores was significantly higher in patients with MDD with ARRB1 ht1 than in those without ht1. The ARRB1 polymorphisms represent promising genetic markers for the prediction of treatment responses to mirtazapine.

Original languageEnglish
Pages (from-to)615-622
Number of pages8
JournalJournal of Psychopharmacology
Volume29
Issue number5
DOIs
Publication statusPublished - 2015 May 5

Fingerprint

Major Depressive Disorder
Haplotypes
Therapeutics
Arrestin
mirtazapine
Genetic Markers
Antidepressive Agents
Single Nucleotide Polymorphism
Genotype
Depression

Keywords

  • major depressive disorder
  • mirtazapine
  • polymorphism
  • treatment response
  • β-Arrestin 1

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Psychiatry and Mental health

Cite this

Association of ARRB1 polymorphisms with the risk of major depressive disorder and with treatment response to mirtazapine. / Chang, Hun Soo; Won, Eun Soo; Lee, Hwa Young; Ham, Byung-Joo; Kim, Yong Gu; Lee, Min-Soo.

In: Journal of Psychopharmacology, Vol. 29, No. 5, 05.05.2015, p. 615-622.

Research output: Contribution to journalArticle

Chang, Hun Soo ; Won, Eun Soo ; Lee, Hwa Young ; Ham, Byung-Joo ; Kim, Yong Gu ; Lee, Min-Soo. / Association of ARRB1 polymorphisms with the risk of major depressive disorder and with treatment response to mirtazapine. In: Journal of Psychopharmacology. 2015 ; Vol. 29, No. 5. pp. 615-622.
@article{82e5120aa9c545a1ad3d57e7c3e8fe9f,
title = "Association of ARRB1 polymorphisms with the risk of major depressive disorder and with treatment response to mirtazapine",
abstract = "β-Arrestin 1 is known to be involved in the pathophysiology of major depressive disorder (MDD) and in the underlying mechanism of action of antidepressant therapies. After we screened 39 ARRB1 polymorphisms, we investigated the associations of seven ARRB1 single-nucleotide polymorphisms (SNPs) with the risk of MDD in 270 patients with MDD and 204 normal subjects, and with mirtazapine treatment response in patients with MDD. The genotype distributions of -132C>T and IVS1+85T>C showed significant deviations from Hardy-Weinberg equilibrium in patients with MDD but not in normal subjects. After four and 12 weeks of mirtazapine treatment, the proportion of haplotype 1 (ht1) carriers was significantly higher in remitters than in non-remitters after corrections for multiple comparisons (corrected p=0.006 and 0.014 at four and 12 weeks, respectively). After eight and 12 weeks of treatment, scores on the 21-item Hamilton Depression Rating Scale (HAMD21) were significantly lower in patients with MDD with ARRB1 ht1 than in those without ht1. Similarly, after 8 and 12 weeks of treatment, the percent reduction in HAMD21 scores was significantly higher in patients with MDD with ARRB1 ht1 than in those without ht1. The ARRB1 polymorphisms represent promising genetic markers for the prediction of treatment responses to mirtazapine.",
keywords = "major depressive disorder, mirtazapine, polymorphism, treatment response, β-Arrestin 1",
author = "Chang, {Hun Soo} and Won, {Eun Soo} and Lee, {Hwa Young} and Byung-Joo Ham and Kim, {Yong Gu} and Min-Soo Lee",
year = "2015",
month = "5",
day = "5",
doi = "10.1177/0269881114554273",
language = "English",
volume = "29",
pages = "615--622",
journal = "Journal of Psychopharmacology",
issn = "0269-8811",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Association of ARRB1 polymorphisms with the risk of major depressive disorder and with treatment response to mirtazapine

AU - Chang, Hun Soo

AU - Won, Eun Soo

AU - Lee, Hwa Young

AU - Ham, Byung-Joo

AU - Kim, Yong Gu

AU - Lee, Min-Soo

PY - 2015/5/5

Y1 - 2015/5/5

N2 - β-Arrestin 1 is known to be involved in the pathophysiology of major depressive disorder (MDD) and in the underlying mechanism of action of antidepressant therapies. After we screened 39 ARRB1 polymorphisms, we investigated the associations of seven ARRB1 single-nucleotide polymorphisms (SNPs) with the risk of MDD in 270 patients with MDD and 204 normal subjects, and with mirtazapine treatment response in patients with MDD. The genotype distributions of -132C>T and IVS1+85T>C showed significant deviations from Hardy-Weinberg equilibrium in patients with MDD but not in normal subjects. After four and 12 weeks of mirtazapine treatment, the proportion of haplotype 1 (ht1) carriers was significantly higher in remitters than in non-remitters after corrections for multiple comparisons (corrected p=0.006 and 0.014 at four and 12 weeks, respectively). After eight and 12 weeks of treatment, scores on the 21-item Hamilton Depression Rating Scale (HAMD21) were significantly lower in patients with MDD with ARRB1 ht1 than in those without ht1. Similarly, after 8 and 12 weeks of treatment, the percent reduction in HAMD21 scores was significantly higher in patients with MDD with ARRB1 ht1 than in those without ht1. The ARRB1 polymorphisms represent promising genetic markers for the prediction of treatment responses to mirtazapine.

AB - β-Arrestin 1 is known to be involved in the pathophysiology of major depressive disorder (MDD) and in the underlying mechanism of action of antidepressant therapies. After we screened 39 ARRB1 polymorphisms, we investigated the associations of seven ARRB1 single-nucleotide polymorphisms (SNPs) with the risk of MDD in 270 patients with MDD and 204 normal subjects, and with mirtazapine treatment response in patients with MDD. The genotype distributions of -132C>T and IVS1+85T>C showed significant deviations from Hardy-Weinberg equilibrium in patients with MDD but not in normal subjects. After four and 12 weeks of mirtazapine treatment, the proportion of haplotype 1 (ht1) carriers was significantly higher in remitters than in non-remitters after corrections for multiple comparisons (corrected p=0.006 and 0.014 at four and 12 weeks, respectively). After eight and 12 weeks of treatment, scores on the 21-item Hamilton Depression Rating Scale (HAMD21) were significantly lower in patients with MDD with ARRB1 ht1 than in those without ht1. Similarly, after 8 and 12 weeks of treatment, the percent reduction in HAMD21 scores was significantly higher in patients with MDD with ARRB1 ht1 than in those without ht1. The ARRB1 polymorphisms represent promising genetic markers for the prediction of treatment responses to mirtazapine.

KW - major depressive disorder

KW - mirtazapine

KW - polymorphism

KW - treatment response

KW - β-Arrestin 1

UR - http://www.scopus.com/inward/record.url?scp=84930674741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930674741&partnerID=8YFLogxK

U2 - 10.1177/0269881114554273

DO - 10.1177/0269881114554273

M3 - Article

VL - 29

SP - 615

EP - 622

JO - Journal of Psychopharmacology

JF - Journal of Psychopharmacology

SN - 0269-8811

IS - 5

ER -